Maintenance Treatment
50 articles
PARP Inhibitors for Pancreatic Cancer Maintenance Treatment
Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.
Research Highlights from ASCO GI 2026
The latest research on drugs targeting KRAS and new immuotherapy combinations were among the highlights of ASCO GI 2026.
PLATINUM Clinical Trial Actively Recruiting
The PLATINUM clinical trial, for patients with BRCA and PALB2 mutations, seeks participants. Dr. Andrew Ko outlines the trial.
New Trial to Find Biomarkers to Guide Treatment
Drs. Jennifer Knox and Elizabeth Jaffee lead the PASS-01 trial using biomarkers and other measures to choose individualized treatment.
Exploiting DNA Mutations For Pancreatic Cancer Treatment
Dr. James Cleary explains how the researchers at Dana-Farber are looking to make PARP inhibitors even more effective for pancreatic cancer patients.
Pancreatic Cancer Science—2021 in Review
As the year winds down Let’s Win provides an overall look at the highlights of 2021 in pancreatic cancer science.
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
Pancreatic Cancer Research Builds Upon Strengths
The September 2023 AACR Special Conference on Pancreatic Cancer focused on the latest research in KRAS, chemotherapy, and cachexia, among other topics.
A Maintenance Trial for Patients with BRCA or PALB2 Mutations
A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.
Looking Back at the Year in Research: 2019
Research highlights of 2019 include: approval of a PARP inhibitor, artificial intelligence to diagnose pancreatic cysts, and updated radiation guidelines.
New Study Aims to Reduce Recurrence Risk for Select Patients
Dr. Kim A. Reiss is leading a study of the PARP inhibitor olaparib to delay or prevent a recurrence of surgically removed pancreatic cancer.
PARP Inhibitor as Maintenance for Pancreatic Cancer Patients with BRCA1, BRCA2, or PALB2 Mutations
A new clinical trial tests a PARP inhibitor as maintenance treatment for pancreatic cancer patients with BRCA1/2 or PALB2 mutations.
A Potential Role for PARP Inhibitors in Pancreatic Cancer
Dr. Michael Pishvaian leads research into the possible role of PARP inhibitors in treating pancreatic cancer patients with certain genetic mutations.
AACR Virtual Special Conference on Pancreatic Cancer: Day One Highlights
Let’s Win and the Lustgarten Foundation present highlights of Day One of the AACR Virtual Special Conference on Pancreatic Cancer.
Taking a Look At FAK Inhibitors
Dr. Conan Kinsey is looking at how FAK inhibitors can make immunotherapy more effective in combination with chemotherapy.